

Surveys and Anatomic Pathology Education Programs

Performance Improvement Program in Surgical Pathology PIP/PIPW-D 2021

**Participant Summary** 

This document is available online in e-LAB Solutions Suite.

© 2021 College of American Pathologists. The CAP does not permit reproduction of any substantial portion of the material in this Report without its written authorization. The CAP hereby authorizes participants in the program to use the material in this Report solely for educational purposes within their own institutions. The CAP prohibits use of the material in the Report — and any unauthorized use of the CAP's name or logo — in connection with promotional efforts by marketers of laboratory equipment, reagents, materials, or services. Data from this program do not necessarily indicate the superiority or inferiority of instruments, reagents, or other materials used by participating laboratories. Use of these data to suggest such superiority or inferiority may be deceptive and misleading. The CAP will take all steps open to it under the law to prevent unauthorized reproduction of substantial portions of the material in this Report, deceptive use of any such material, and any unauthorized use of the CAP's name or logo in connection with promotional efforts by marketers of laboratory equipment, reagents, materials, or services.

## 2021 PIP/PIPW-D **PARTICIPANT SUMMARY**

## **Program Update**

This report summarizes the diagnostic responses for set D of the 2021 Performance Improvement Program in Surgical Pathology (PIP & PIPW).

A tabulation of the responses to the supplementary questions is not included since these are intended for educational purposes only.

## SURGICAL PATHOLOGY COMMITTEE

Aaron Auerbach, MD FCAP, Chair Raul Gonzalez, MD FCAP, Vice-Chair

Oyedele A. Adeyi, MBBS FCAP Nadine S. Aguilera, MD FCAP Vijayalakshmi Ananthanarayanan, MD, MBBS FCAP Anwar Sultana Sabiha Raza, MD FCAP Phyu P. Aung, MD PhD FCAP Byron Barksdale, Jr. Deborah Ann Belchis, MD FCAP Lynden Praul Bowden III, MD FCAP Miriam Conces, MD FCAP Rajan Dewar, MD, PhD FCAP

Xiaoyin Jiang, MD FCAP Vinita Parkash, MD FCAP Safia N. Salaria, MD FCAP Lauren Schwartz, MD FCAP Robert A. Schwartz, MD FCAP Sabrina C. Sopha, MD FCAP Justin M. Wells, MD FCAP Danielle E. Westfall, MD FCAP

	Diagnos	is cinar cell carcinoma				
	(2414) AC	inal celi carcilloma	PIP Particip	oants	PIPW Partic	cipants
	Code	Diagnosis	No.	%	No.	%
	2414	Acinar cell carcinoma	6046	99.3	346	89.2
	5743	Mixed acinar-neuroendocrine carcinoma	10	0.2	4	1.0
	2298	Pancreatic neuroendocrine tumor	13	0.2	14	3.6
-3,	2418	Pancreatoblastoma	4	0.1	5	1.3
02	2300	Solid pseudopapillary neoplasm	13	0.2	19	4.9
Case # 2021-31	Technica	Quality of Slide	PIP Particip	oants		
	Rating	Glass Slide Evaluation	No.	%		
	001	Excellent	3159	56.6		
	002		1022	18.3		
	003	Satisfactory	1289	23.1		
	004		99	1.8		
	005	Unsatisfactory	11	0.2		

		PIP Par	ticipants	PIPW Partio	cipants
Code	Diagnosis	No	. %	No.	%
5744	Abnormal villous morphology associated with trisomy	2	<0.1	5	1.3
2664	Complete hydatidiform mole	6050	99.5	341	90.9
2524	Partial hydatidiform mole	22	0.4	18	4.8
5745	Placental mesenchymal dysplasia	3	3 <0.1	2	0.5
5746	Spontaneous hydropic abortion	3	3 <0.1	9	2.4
echnica	al Quality of Slide			_	
		PIP Par	ticipants		
Rating	Glass Slide Evaluation	No	. %		
001	Excellent	3015	54.4		
002		1088	19.6		
003	Satisfactory	1305	23.5		
004		126	3 2.3		
005	Unsatisfactory	10	0.2		

	Diagnos						
	(2468) E	mbryonal rhabdomyosarcoma, metastatic	٦ ا	PIP Particip	ants	PIPW Partic	cipants
	Code	Diagnosis	$\rfloor  $	No.	%	No.	%
	2136	Desmoplastic small round cell tumor		32	0.5	28	7.7
	2468	Embryonal rhabdomyosarcoma, metastatic		6034	99.1	303	82.8
33	5747	Hepatoblastoma, small cell undifferentiated type		11	0.2	14	3.8
21-3	2068	Synovial sarcoma		4	0.1	6	1.6
20;	5748	Wilms tumor, metastatic		8	0.1	15	4.1
Case # 2021-33		al Quality of Slide	۱[	PIP Particip	ants		
	Ratin	Glass Slide Evaluation		No.	%		
	001	Excellent		2912	53.0		
	002			1134	20.7		
	003	Satisfactory		1321	24.1		
	004			106	1.9		
	005	Unsatisfactory		16	0.3		

	Desmoid-type fibromatosis	PIP Particip	oants	PIPW Partio	ipants
Code	Diagnosis	No.	%	No.	%
2499	Dermatofibrosarcoma protuberans	19	0.3	12	3.3
5749	Desmoid-type fibromatosis	6057	99.5	341	93.9
1361	Epithelioid trophoblastic tumor	0	0.0	5	1.4
2795	Inflammatory myofibroblastic tumor	10	0.2	2	0.6
5750	Keloid	0	0.0	3	0.8
Technic	al Quality of Slide			1	
		PIP Particip	oants		
Technic Rating	al Quality of Slide  Glass Slide Evaluation	PIP Particiț No.			
		- I I	oants		
Rating	Glass Slide Evaluation	No.	oants %		
Rating 001	Glass Slide Evaluation	<b>No.</b> 3107	oants % 58.6		
001 002	Glass Slide Evaluation  Excellent	No. 3107 913	58.6 17.2		

Diagnos	is				
	vasive high-grade urothelial carcinoma				
		PIP Particip	ants	PIPW Partio	cipants
Code	Diagnosis	No.	%	No.	%
0040		40			40.0
2019	Collecting duct carcinoma	42	0.7	44	12.3
5751	Invasive high-grade urothelial carcinoma	6024	99.0	282	79.0
1849	Medullary carcinoma	8	0.1	7	2.0
5752	Metastatic squamous cell carcinoma	9	0.1	20	5.6
1797	Papillary renal cell carcinoma	4	0.1	4	1.1
Toobnico	Loughty of Clida				
rechnica	Quality of Slide	PIP Particip	ante		
Rating	Glass Slide Evaluation	No.	wants %		
001	Excellent	2816	51.6		
002		1114	20.4		
003	Satisfactory	1392	25.5		
004	,	116	2.1		

	Diagnos					
	(5733) Hi	gh-grade serous carcinoma				
			PIP Partici	oants	PIPW Partio	cipants
	Code	Diagnosis	No.	%	No.	%
	5733	High-grade serous carcinoma	6030	99.2	307	86.7
	5734	Low-grade serous carcinoma	30	0.5	12	3.4
	2414	Metastatic carcinoma of the breast	1	<0.1	4	1.1
ဖွ	5753	Metastatic clear cell carcinoma of the ovary	4	<0.1	7	2.0
:021-3	5754	Metastatic endometrioid carcinoma of the ovary	17	0.3	24	6.8
Case # 2021-36	5755	Metastatic HPV-related endocervical adenocarcinoma	0	0.0	0	0.0
ပိ	Technica	Quality of Slide				
			PIP Partici	oants		
	Rating	Glass Slide Evaluation	No.	%		
	001	Excellent	2989	54.7		
	002		1047	19.2		
	003	Satisfactory	1306	23.9		
	004		108	2.0		
	005	Unsatisfactory	13	0.2		

	Diagnos	
	(2352) O	ncc
	Code	D
	1663	Cl
	1665	CI
	5756	Er
-37	1538	Hi
021	2352	ar O
# 5	2344	Τι
Case	Technica	
	Rating	G
	001	Ex
	002	_

		PIP Partici	PIP Participants		cipants
Code	Diagnosis	No.	%	No.	%
1663	Chromophobe renal cell carcinoma, eosinophilic variant	66	1.1	41	11.6
1665	Clear cell renal cell carcinoma	2	<0.1	5	1.4
5756	Embryonal rhabdomyosarcoma	27	0.4	29	8.2
1538	High-grade B-cell lymphoma with MYC and BCL2 rearrangements	40	0.7	15	4.2
2352	Oncocytoma	5942	97.7	260	73.8
2344	Tubulocystic renal cell carcinoma	5	0.1	3	0.8

Technica	Technical Quality of Slide									
		PIP Participants								
Rating	Glass Slide Evaluation	No. %								
001	Excellent	2729 50.5								
002		1086 20.1								
003	Satisfactory	1388 25.7								
004		151 2.8								
005	Unsatisfactory	51 0.9								

Diagnos	sis				
(1649) S	olitary fibrous tumor				
		PIP Particip	oants	PIPW Partio	cipants
Code	Diagnosis	No.	%	No.	%
5749	Desmoid-type fibromatosis	18	0.3	8	2.3
1441	Mesenchymal chondrosarcoma	1	<0.1	3	0.9
1649	Solitary fibrous tumor	5953	97.8	251	72.1
1753	Spindle cell lipoma, fat poor	97	1.6	68	19.5
2068	Synovial sarcoma	15	0.3	18	5.2
Tb-:-	LOWER AT OLD				
rechnica	l Quality of Slide	PIP Particip	ante	1	
Rating	Glass Slide Evaluation	No.	% %		
rtating	Glass Glas Evaluation	110.	70	_	
001	Excellent	2649	48.9		
002		1088	20.1		
003	Satisfactory	1365	25.2		
004	•	170	3.1		
005	Unsatisfactory	147	2.7		

	Diagnos (2081) A	sis dult granulosa cell tumor				
			PIP Partici	pants	PIPW Partio	cipants
	Code	Diagnosis	No.	%	No.	%
	2081	Adult granulosa cell tumor	6045	99.4	313	90.4
	2690	Endometrioid adenocarcinoma with sex cord-like differentiation	13	0.2	11	3.2
39	1886	Juvenile granulosa cell tumor	10	0.2	10	2.9
21-	2343	Small cell carcinoma, hypercalcemic type	2	<0.1	1	0.3
<b>‡</b> 20)	2546	Steroid cell tumor	13	0.2	11	3.2
Case # 2021-39	Technica	l Quality of Slide				
ပိ			PIP Partici	pants		
	Rating	Glass Slide Evaluation	No.	%		
	001	Excellent	2671	49.5		
	001	Excellent	971	18.0		
	002	Satisfactory	1388	25.8		
	003	Catistactory	268	5.0		
	004	Unacticfactory				
	005	Unsatisfactory	92	1.7		

Diagnos (2716) Di	<b>is</b> ffuse large B-cell lymphoma, not otherwise s	pecified			
		PIP Particip	oants	PIPW Partic	ipants
Code	Diagnosis	No.	%	No.	%
0000	a	•			
2268	Classic Hodgkin lymphoma	9	0.1	4	1.1
2716	Diffuse large B-cell lymphoma, not otherwise specified	5961	98.4	294	86.0
5757	EBV-positive diffuse large B cell lymphoma, not otherwise specified	52	0.9	3	0.9
5758	High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement	37	0.6	39	11.4
2476	Metastatic carcinoma	1	<0.1	2	0.6
Technical	Quality of Slide				
		PIP Partici	oants		
Rating	Glass Slide Evaluation	No.	%		
				-	
001	Excellent	2937	54.5		
002		1046	19.4		
003	Satisfactory	1292	23.9		
004	-	110	2.0		
005	Unsatisfactory	13	0.2		

The CAP Surgical Pathology Committee relies on the donations of tissue blocks to sustain the PIP glass slide Proficiency Testing Survey and greatly appreciates and thanks all who have donated tissue blocks for use in the PIP Surveys. At the end of each year, case donors who submitted cases during the year will be listed in the PIP-D PSR by individual or institution. Due to patient confidentiality, individual cases will not be listed by institution.

The CAP Surgical Pathology Committee would like to thank the following individual or institution for its generous donations of tissue blocks in 2021 for use in PIP Proficiency Testing Surveys:

Oyedele Adeyi, MBBS
Sara Jiang, MD
Thuy Means, MD
James Mc Cool, MD
Isabel Almira-Suarez, MD
Kossivi Dantey, MD
Sabrina Sopha, MD

